

\*For correspondence: prashant.mishra@utsouthwestern.edu

## Abstract

Sarcopenia, or age-associated muscle atrophy, is a progressive condition which affects ~10-30% of the human geriatric population (1, 2). A number of contributors to sarcopenia have been proposed, including the progressive loss of muscle stem cells (MuSCs) with age. However, studies in mice have provided evidence that MuSC depletion is not sufficient to induce sarcopenia (3, 4). We recently showed that in response to age-associated mitochondrial damage, MuSCs self-remove by fusing with neighboring myofibers, which depletes the stem cell population of damaged progenitors (5). Here, we show that MuSC-myofiber fusion is sufficient to initiate myofiber atrophy in mice, which limits their motor function and lifespan. Conversely, inhibition of MuSC-myofiber fusion blocks myofiber atrophy with age, with a concomitant increase in the maximum lifespan of animals. These findings suggest a model where the accumulation fusion of damaged MuSCs with adult myofibers is a key driving feature of sarcopenia, and resolves the findings that MuSC depletion on its own does not initiate myofiber atrophy.

In mammals, a number of studies indicate that MuSCs decline in numbers with age (6-9), suggesting that the limited regenerative capacity of aged muscle contributes to myofiber atrophy. However, in two recent studies (3, 4) in mice, MuSCs were depleted by conditional expression of a diphtheria toxin allele (DTA) at early age. Neither study observed an accelerated decline in myofiber size with age, calling into the question the contribution of MuSCs to age-associated atrophy.

In response to mitochondrial electron transport chain (ETC) dysfunction or environmental toxins, muscle stem cells are induced to directly fuse into neighboring adult myofibers (5, 10). These fusion events contribute to the decline in MuSC numbers with age; however, the consequences for the accepting myofiber are unknown (Fig. 1A). To address this, we used a conditional allele targeting Cox10, a critical assembly component of mitochondrial complex IV (11), combined with the tamoxifen-inducible Pax7-CreERT2 driver (12), to induce ETC dysfunction in adult MuSCs. Inhibition of complex IV function triggered the rapid removal of MuSCs, by inducing fusion with neighboring myofibers (Fig. S1A,B), consistent with previous results (5). We treated 6-week old mice with tamoxifen to induce Cox10 deletion in adult MuSCs, and followed subjects as they aged (Fig. 1B). Tamoxifen-treated Cox10 (Pax7-CreERT2; Cox10flox/flox) animals had a median lifespan of 578 days, and a maximum lifespan of 805 days, which was significantly shorter than tamoxifen-treated wild-type (wt) animals (Pax7-Cre<sup>ERT2</sup>; Cox10<sup>+/+</sup>, median 861.5 days, maximum 965 days) (Fig. 1B). Histologic examination at 12 months of age did not reveal signs of inflammation or fibrosis in muscles from Cox10 animals (Fig. S1C,D). However, Cox10 animals exhibited decreased size of the tibialis anterior (TA) muscle and decreased crosssectional area of myofibers in multiple muscle groups (Fig. 1C-E, Fig. S1E). Myofibers from Cox10 animals had significant impairments in mitochondrial cytochrome c oxidase (COX) activity (Fig. 1F, Fig. S1F). Cox10 animals also exhibited deficits in muscle performance, including decreased grip-strength and maximal running distance (Fig. 1G,H). Thus, inducing

ETC dysfunction in MuSCs is sufficient to decrease muscle and myofiber size, motor performance and lifespan as mice age.

In parallel, we assessed animals in which Cox10 was co-deleted with either Myomaker or Scinderin in the MuSC compartment ('Cox10,Myk' or 'Cox10,Scin'). Myomaker is a transmembrane protein required for MuSC fusion, while Scinderin is an actin-network reorganizing protein that is specifically required for MuSC-myofiber fusion (5, 13, 14). Cox10,Myk and Cox10,Scin animals did not experience shortened lifespans, myofiber or muscle atrophy, mitochondrial dysfunction, or motor function deficits (Fig. 1B-H), indicating that MuSC-myofiber fusion is required for the initiation of sarcopenic-features in this genetic model.

We observed the presence of COX-negative, SDH-positive (COX-SDH+) fibers in 12 month old *Cox10* muscle, similar to histologic characteristics observed in muscle biopsies of elderly human patients (*15-17*) (Fig. S1G). COX-SDH+ fibers were not observed in wild-type, *Cox10,Myk* or *Cox10,Scin* animals (Fig. S1H). These results indicate that loss of ETC function in MuSCs is sufficient to accelerate myofiber atrophy with age-associated histologic features, and suggest that inhibition of MuSC-myofiber fusion may be protective in age-associated atrophy.

We next assessed the role of MuSC-myofiber fusion during normal aging by comparing wild-type mice with animals where Myomaker or Scinderin were conditionally deleted in MuSCs at 6 weeks of age (*Myk*: Pax7-Cre<sup>ERT2</sup>; Myk<sup>flox/flox</sup> or *Scin*: Pax7-Cre<sup>ERT2</sup>; Scin<sup>flox/flox</sup>). *Myk* and *Scin* animals exhibited extensions in maximal lifespan (1156 days (*Myk*) and 1178 days (*Scin*) vs. 965 days (wild-type)), without significant changes in median survival (Fig. 2A). In wild-type animals, myofibers maintain size between 2 and 12 months of age, followed by atrophy (Figure 2B,C). Myofiber atrophy was inhibited in muscles from *Scin* and *Myk* animals (Fig. 2B,C). Similarly, the absolute TA muscle weight increases from 2 to 12 months, but then declines by 24 and 30 months of age in wild-type animals (Fig. 2D). In *Scin* and *Myk* animals, muscle weight is

retained at 24 and 30 months of age (Fig. 2D). We observed similar trends after normalizing for body weight (Fig. S1I).

Together, these results suggest a new model for the initiation and progression of myofiber atrophy during aging (Fig. 1A). MuSCs are known to accumulate mitochondrial genome mutations and dysfunction and are induced to fuse with neighboring myofibers with age (5, 18, 19). These fusion events clear damaged MuSCs from the stem cell population; however, adult myofibers accumulate the contents of damaged MuSCs, which accelerates the development of sarcopenic features and limits their maximal lifespan. Inhibiting MuSC-myofiber fusion blocks myofiber atrophy and can increase the maximal lifespan of mice. Interestingly, sporadic mitochondrial dysfunction within myofibers are a key feature of human sarcopenia (15-17). A number of studies indicate that segments of aged myofibers contain clonal expansions of mutant mitochondrial genomes that co-localize with electron transport chain defects (20-22), suggesting that mitochondrial defects within myofibers drive atrophy during aging (23-25). Thus, we propose that it is not the decline of MuSCs that significantly contributes to muscle aging, but instead the absorption of damaged mitochondrial genomes from aging MuSCs. Future work examining the biology and genotypes characteristic of aged MuSCs in human specimens will be important to validate this model.

Acknowledgements: We thank Eric Olson for providing  $Myk^{flox}$  mice, and Michael Glogauer for providing  $Scin^{flox}$  mice. Funding: This work was supported by funding from the United Mitochondrial Disease Foundation (Research Grant to P.M.), the National Institutes of Health (1DP2ES030449-01 from NIEHS, 1R01AR073217-01 from NIAMS) to P.M., the Moody Medical Research Institute (Research Grant to P.M.), and the MMK Foundation (Research Grant to P.M.). Author Contributions: X.W. and P.M. conceived the project. X.W. performed experiments. X.W. and P.M. prepared the figures and manuscript. Competing interests: The authors declare no competing interests. Data availability: All data and materials are provided within the manuscript and supplementary materials, or upon request.




Figure 1: Complex IV dysfunction in MuSCs induces pre-mature sarcopenia and limits lifespan in mice.

A) Overall model: Induced mitochondrial dysfunction in MuSCs triggers them to fuse into adjacent adult myofibers (red arrows) which initiates sarcopenic features. B) Survival curve of mice with the indicated genotype, following tamoxifen administration at 6 weeks of age. A subset of mice were euthanized at 12 months of age for analysis. p-values represent comparison with wt survival curves. C) Representative immunofluorescent images from tibialis anterior (TA) cross-sections of animals at 12 months of age. Muscle boundaries are visualized

by staining with WGA (green). Scale bar,  $50 \, \mu m$ . D) Histogram of myofiber cross-sectional area from TA muscles of wild-type and Cox10 animals. E) TA muscle weight (normalized to body weight) for animals of the indicated genotype at 12 months of age. F) Representative histochemistry of COX activity in muscle cross-sections from TA muscles at 12 months of age. Scale bar,  $50 \, \mu m$ . G) Hindlimb grip strength measurements from animals at 12 months of age. H) Maximal treadmill distance of animals at 12 months of age. Box plots indicate the interquartile ranges; whiskers are plotted with the Tukey method. Statistical analysis was performed using 1-way ANOVA (E,H), Kruskal-Wallis (G), log-rank test (B), or Kolmogorov-Smirnov test (D), with adjustments for multiple comparisons.




Figure 2: Inhibition of MuSC-myofiber fusion protects animals from myofiber atrophy during aging.

A) Survival curves of mice of the indicated genotype, following tamoxifen administration at 6 weeks of age. p-values reflect comparisons with wild-type survival curve. A subset of animals were euthanized at 2, 12, 24 and 30 months of age for analysis. B) Representative immunofluorescent images from TA cross-sections. Muscle boundaries are visualized by WGA staining (green). Scale bar, 50 μm. C) Quantitation of myofiber cross-sectional area from TA muscles. 200 fibers were analyzed from n=5 mice per group. p-values reflect comparisons with 2 month old group. D) TA muscle weight at the indicated age. n=5 mice per group. p-values reflect comparisons with 12 month old group. Box plots indicate the inter-quartile ranges; whiskers indicate the 10<sup>th</sup> and 90<sup>th</sup> percentile. Statistical analysis was performed using 2-way ANOVA (C,D) or log-rank test (A) with adjustments for multiple comparisons.

## References

- 1. G. Shafiee, A. Keshtkar, A. Soltani, Z. Ahadi, B. Larijani, R. Heshmat, Prevalence of sarcopenia in the world: a systematic review and meta- analysis of general population studies. *Journal of diabetes and metabolic disorders* **16**, 21 (2017)10.1186/s40200-017-0302-x).
- 2. D. Bertschi, C. M. Kiss, N. Beerli, R. W. Kressig, Sarcopenia in hospitalized geriatric patients: insights into prevalence and associated parameters using new EWGSOP2 guidelines. *European journal of clinical nutrition* **75**, 653-660 (2021); published online EpubApr (10.1038/s41430-020-00780-7).
- 3. C. S. Fry, J. D. Lee, J. Mula, T. J. Kirby, J. R. Jackson, F. Liu, L. Yang, C. L. Mendias, E. E. Dupont-Versteegden, J. J. McCarthy, C. A. Peterson, Inducible depletion of satellite cells in adult, sedentary mice impairs muscle regenerative capacity without affecting sarcopenia. *Nature medicine* **21**, 76-80 (2015); published online EpubJan (10.1038/nm.3710).
- 4. A. C. Keefe, J. A. Lawson, S. D. Flygare, Z. D. Fox, M. P. Colasanto, S. J. Mathew, M. Yandell, G. Kardon, Muscle stem cells contribute to myofibres in sedentary adult mice. *Nature communications* **6**, 7087 (2015); published online EpubMay 14 (10.1038/ncomms8087).
- 5. X. Wang, S. D. Shelton, B. Bordieanu, A. R. Frank, Y. Yi, S. S. K. Venigalla, Z. Gu, N. P. Lenser, M. Glogauer, N. S. Chandel, H. Zhao, Z. Zhao, D. G. McFadden, P. Mishra, Scinderin promotes fusion of electron transport chain dysfunctional muscle stem cells with myofibers. *Nature aging* **2**, 155-169 (2022)10.1038/s43587-021-00164-x).
- 6. A. S. Brack, H. Bildsoe, S. M. Hughes, Evidence that satellite cell decrement contributes to preferential decline in nuclear number from large fibres during murine age-related muscle atrophy. *Journal of cell science* **118**, 4813-4821 (2005); published online EpubOct 15 (10.1242/jcs.02602).
- 7. M. H. Snow, The effects of aging on satellite cells in skeletal muscles of mice and rats. *Cell and tissue research* **185**, 399-408 (1977); published online EpubDec 19 (10.1007/BF00220299).
- 8. M. C. Gibson, E. Schultz, Age-related differences in absolute numbers of skeletal muscle satellite cells. *Muscle & nerve* **6**, 574-580 (1983); published online EpubOct (10.1002/mus.880060807).
- 9. V. Renault, L. E. Thornell, P. O. Eriksson, G. Butler-Browne, V. Mouly, Regenerative potential of human skeletal muscle during aging. *Aging cell* **1**, 132-139 (2002); published online EpubDec (10.1046/j.1474-9728.2002.00017.x).
- A. Der Vartanian, M. Quetin, S. Michineau, F. Aurade, S. Hayashi, C. Dubois, D. Rocancourt, B. Drayton-Libotte, A. Szegedi, M. Buckingham, S. J. Conway, M. Gervais, F. Relaix, PAX3 Confers Functional Heterogeneity in Skeletal Muscle Stem Cell Responses to Environmental Stress. *Cell stem cell* 24, 958-973 e959 (2019); published online EpubJun 6 (10.1016/j.stem.2019.03.019).
- 11. F. Diaz, C. K. Thomas, S. Garcia, D. Hernandez, C. T. Moraes, Mice lacking COX10 in skeletal muscle recapitulate the phenotype of progressive mitochondrial myopathies associated with cytochrome c oxidase deficiency. *Human molecular genetics* **14**, 2737-2748 (2005); published online EpubSep 15 (10.1093/hmg/ddi307).
- 12. M. M. Murphy, J. A. Lawson, S. J. Mathew, D. A. Hutcheson, G. Kardon, Satellite cells, connective tissue fibroblasts and their interactions are crucial for muscle regeneration. *Development* **138**, 3625-3637 (2011); published online EpubSep (10.1242/dev.064162).
- 13. D. P. Millay, L. B. Sutherland, R. Bassel-Duby, E. N. Olson, Myomaker is essential for muscle regeneration. *Genes & development* **28**, 1641-1646 (2014); published online EpubAug 1 (10.1101/gad.247205.114).

- 14. D. P. Millay, J. R. O'Rourke, L. B. Sutherland, S. Bezprozvannaya, J. M. Shelton, R. Bassel-Duby, E. N. Olson, Myomaker is a membrane activator of myoblast fusion and muscle formation. *Nature* **499**, 301-305 (2013); published online EpubJul 18 (10.1038/nature12343).
- 15. P. Yu-Wai-Man, J. Lai-Cheong, G. M. Borthwick, L. He, G. A. Taylor, L. C. Greaves, R. W. Taylor, P. G. Griffiths, D. M. Turnbull, Somatic mitochondrial DNA deletions accumulate to high levels in aging human extraocular muscles. *Investigative ophthalmology & visual science* **51**, 3347-3353 (2010); published online EpubJul (10.1167/iovs.09-4660).
- 16. J. Muller-Hocker, K. Schneiderbanger, F. H. Stefani, B. Kadenbach, Progressive loss of cytochrome c oxidase in the human extraocular muscles in ageing--a cytochemical-immunohistochemical study. *Mutation research* **275**, 115-124 (1992); published online EpubSep (10.1016/0921-8734(92)90016-i).
- 17. J. Muller-Hocker, Cytochrome c oxidase deficient fibres in the limb muscle and diaphragm of man without muscular disease: an age-related alteration. *Journal of the neurological sciences* **100**, 14-21 (1990); published online EpubDec (10.1016/0022-510x(90)90006-9).
- 18. L. Garcia-Prat, M. Martinez-Vicente, E. Perdiguero, L. Ortet, J. Rodriguez-Ubreva, E. Rebollo, V. Ruiz-Bonilla, S. Gutarra, E. Ballestar, A. L. Serrano, M. Sandri, P. Munoz-Canoves, Autophagy maintains stemness by preventing senescence. *Nature* **529**, 37-42 (2016); published online EpubJan 7 (10.1038/nature16187).
- H. Zhang, D. Ryu, Y. Wu, K. Gariani, X. Wang, P. Luan, D. D'Amico, E. R. Ropelle, M. P. Lutolf, R. Aebersold, K. Schoonjans, K. J. Menzies, J. Auwerx, NAD(+) repletion improves mitochondrial and stem cell function and enhances life span in mice. *Science* 352, 1436-1443 (2016); published online EpubJun 17 (10.1126/science.aaf2693).
- 20. A. Herbst, C. C. Lee, A. R. Vandiver, J. M. Aiken, D. McKenzie, A. Hoang, D. Allison, N. Liu, J. Wanagat, Mitochondrial DNA deletion mutations increase exponentially with age in human skeletal muscle. *Aging clinical and experimental research* **33**, 1811-1820 (2021); published online EpubJul (10.1007/s40520-020-01698-7).
- 21. J. Wanagat, Z. Cao, P. Pathare, J. M. Aiken, Mitochondrial DNA deletion mutations colocalize with segmental electron transport system abnormalities, muscle fiber atrophy, fiber splitting, and oxidative damage in sarcopenia. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* **15**, 322-332 (2001); published online EpubFeb (10.1096/fj.00-0320com).
- 22. Z. Cao, J. Wanagat, S. H. McKiernan, J. M. Aiken, Mitochondrial DNA deletion mutations are concomitant with ragged red regions of individual, aged muscle fibers: analysis by laser-capture microdissection. *Nucleic acids research* **29**, 4502-4508 (2001); published online EpubNov 1 (10.1093/nar/29.21.4502).
- 23. A. Herbst, J. Wanagat, N. Cheema, K. Widjaja, D. McKenzie, J. M. Aiken, Latent mitochondrial DNA deletion mutations drive muscle fiber loss at old age. *Aging cell* **15**, 1132-1139 (2016); published online EpubDec (10.1111/acel.12520).
- 24. A. Herbst, J. W. Pak, D. McKenzie, E. Bua, M. Bassiouni, J. M. Aiken, Accumulation of mitochondrial DNA deletion mutations in aged muscle fibers: evidence for a causal role in muscle fiber loss. *The journals of gerontology. Series A, Biological sciences and medical sciences* 62, 235-245 (2007); published online EpubMar (10.1093/gerona/62.3.235).
- 25. N. Cheema, A. Herbst, D. McKenzie, J. M. Aiken, Apoptosis and necrosis mediate skeletal muscle fiber loss in age-induced mitochondrial enzymatic abnormalities. *Aging cell* **14**, 1085-1093 (2015); published online EpubDec (10.1111/acel.12399).